Table 1. Demographics and clinical history of patients with pulmonary extensively drug-resistant TB treated with bedaquiline and delamanid*.
| Pt no. | Country of birth/illness | Age, y/ sex | Risk factor | No. treatments >30 d, case category | Weeks ss+ and c+ before Bdq + Dlm treatment | Weight at baseline (last recorded), kg | MDR TB treatment duration, mo | Length of hospital stay, d | Previous TB drug regimen | Drug resistance before Bdq + Dlm (at end of study) |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | India/India | 20/F | None | 1, failure | 200 | 34 (40) | 50 | NA | Cm, Mfx, Eto, PAS, Cfz, Lzd, Cs, Rfb, Bdq | S, H, R, E, Z, Fq, PAS, Km, Rfb (Lzd, Eto) |
| 2 | UK/the Netherlands | 31/F | Recreational drug user | 8, failure | 4 | 54 (68) | 21 | 567 | H, R, Z, E, Amk, Cm, Cfz, Pto, PAS, Cs, Mpm, Amx/Clv, Clr | S, H, R, E, Z, Fq, Eto, Amk, Lzd |
| 3 | Russia/ Russia | 43/M | Recreational drug user | 1, failure | 62 | 54 (76) | 36 | 887 | Cm, Z, Mfx, Trd, Pto, PAS | H, R, E, Fq, Km |
| 4 | Azerbaijan/Russia | 17/F | None | 1, failure | 20 | 53 (51) | 16 | 256 | Z, Cm, Lfx, Pto, Cs, PAS | H, R, E, Z, Km, Amk, Cm, Fq |
| 5 | Tibet/India | 39/F | None | 2, relapse | 52 | 65 (60) | 18 | 1,140 | H, R, Z, E, Hd H, Mfx, Km, PAS, Lzd, Pto | R, Km, Amk, Cm, Fq, Eto, PAS, Lzd, Hd H, Hd Mfx |
*All patients were sputum smear and culture positive. Amk, amikacin; Amx/Clv, amoxicillin/Clavulanate; Bdq, bedaquiline; c+, culture positive; Cfz, clofazimine; Clr, clarithromycin; Cm, capreomycin; Cs, cycloserine; Dlm, delamanid; E, ethambutol; Eto, ethionamide; Fq, fluoroquinolone; H, isoniazid; Hd, high dose; Km, kanamycin; Lfx, levofloxacin; Lzd, linezolid; MDR TB, multidrug-resistant tuberculosis; Mfx, moxifloxacin; Mpm, meropenem; NA, not available; PAS, para-aminosalicylic acid; Pt, patient; Pto, prothionamide; R, rifampin; Rfb, rifabutin; S, streptomycin; ss+, sputum smear positive; TB, tuberculosis; Trd, terizidone; Z, pyrazinamide.